Tjitske van Engelen

300 Chapter 12 References 1. van der Poll T, van de Veerdonk FL, Scicluna BP, Netea MG. The immunopathology of sepsis and potential therapeutic targets. Nat Rev Immunol. 2017/04/25. 2017;17:407–20. 2. Angus DC, Bindman AB. Achieving Diagnostic Excellence for Sepsis. JAMA. United States; 2022;327:117–8. 3. Slim MA, van Mourik N, Bakkerus L, Fuller K, Acharya L, Giannidis T, et al. Towards personalized medicine: a scoping review of immunotherapy in sepsis. Crit Care. England; 2024;28:183. 4. Gordon AC, Alipanah-Lechner N, Bos LD, Dianti J, Diaz J V, Finfer S, et al. From ICU Syndromes to ICU Subphenotypes: Consensus Report and Recommendations for Developing Precision Medicine in the ICU. Am J Respir Crit Care Med. United States; 2024;210:155–66. 5. Harbeck N, Penault-Llorca F, Cortes J, Gnant M, Houssami N, Poortmans P, et al. Breast cancer. Nat Rev Dis Prim. England; 2019;5:66. 6. van Engelen TSR, Wiersinga WJ, Scicluna BP, van der Poll T. Biomarkers in Sepsis. Crit Care Clin [Internet]. 2018;34:139–52. Available from: https://www.ncbi.nlm.nih.gov/ pubmed/29149935 7. Karakike E, Giamarellos-Bourboulis EJ. Macrophage Activation-Like Syndrome: A Distinct Entity Leading to Early Death in Sepsis. Front Immunol. 2019;10:55. 8. Brands X, de Vries FMC, Uhel F, Haak BW, Peters-Sengers H, Schuurman AR, et al. Plasma Ferritin as Marker of Macrophage Activation-Like Syndrome in Critically Ill Patients With Community-Acquired Pneumonia. Crit Care Med. United States; 2021;49:1901–11. 9. Kyriazopoulou E, Poulakou G, Milionis H, Metallidis S, Adamis G, Tsiakos K, et al. Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial. Nat Med. 2021;27:1752– 60. 10. Papamanoli A, Kalogeropoulos AP, Hotelling J, Yoo J, Grewal P, Predun W, et al. Association of Serum Ferritin Levels and Methylprednisolone Treatment With Outcomes in Nonintubated Patients With Severe COVID-19 Pneumonia. JAMA Netw open. 2021;4:e2127172. 11. Venet F, Monneret G. Advances in the understanding and treatment of sepsis-induced immunosuppression. Nat Rev Nephrol. England; 2018;14:121–37. 12. Torres LK, Pickkers P, van der Poll T. Sepsis-Induced Immunosuppression. Annu Rev Physiol. United States; 2022;84:157–81. 13. van Vught LA, Wiewel MA, Hoogendijk AJ, Frencken JF, Scicluna BP, Klein Klouwenberg PMC, et al. The Host Response in Patients with Sepsis Developing Intensive Care Unitacquired Secondary Infections. Am J Respir Crit Care Med. United States; 2017;196:458–70. 14. Langdon A, Crook N, Dantas G. The effects of antibiotics on the microbiome throughout development and alternative approaches for therapeutic modulation. Genome Med. England; 2016;8:39. 15. Blaser MJ. Antibiotic use and its consequences for the normal microbiome. Science (80- ) [Internet]. 2016/04/30. 2016;352:544–5. Available from: https://www.ncbi.nlm.nih.gov/ pubmed/27126037 16. Clarke TB, Davis KM, Lysenko ES, Zhou AY, Yu Y, Weiser JN. Recognition of peptidoglycan from the microbiota by Nod1 enhances systemic innate immunity. Nat Med [Internet]. 2010/01/19. 2010;16:228–31. Available from: https://www.ncbi.nlm.nih.gov/pubmed/20081863 17. Budden KF, Gellatly SL, Wood DL, Cooper MA, Morrison M, Hugenholtz P, et al. Emerging pathogenic links between microbiota and the gut-lung axis. Nat Rev Microbiol [Internet]. 2016/11/01. 2017;15:55–63. Available from: https://www.ncbi.nlm.nih.gov/pubmed/27694885 18. Merriam-Webster Dictionary [Internet]. [cited 2024 Jul 12]. Available from: https://www. merriam-webster.com/dictionary/diagnosis

RkJQdWJsaXNoZXIy MTk4NDMw